Prostate MRI has been integrated into the diagnostic work-up for men at risk of having clinically significant cancer in multiple clinical care guidelines. Owing to the low false-negative rate of prostate MRI accompanying a sensitivity averaging 91%, we can reduce biopsies (by 30%) and indolent cancer detection, while maintaining (or even improving) detection of significant cancers, compared to systematic biopsy.